CompletedEarly Phase 1NCT04549792
An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses
Studying Ichthyosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Northwestern University
- Principal Investigator
- Amy Paller, MDNorthwestern University
- Intervention
- Ustekinumab(drug)
- Enrollment
- 13 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2021 – 2024
Study locations (1)
- Northwestern University/Lurie Children's Hospital, Chicago, Illinois, United States
Collaborators
Janssen Scientific Affairs, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04549792 on ClinicalTrials.govOther trials for Ichthyosis
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07050810Thera-Clean® Microbubbles System in Patients With Skin DiseasesNorthwestern University
- ENROLLING BY INVITATIONNANCT06330324Reproductive Options in Inherited Skin DiseasesMaastricht University Medical Center
- RECRUITINGNANCT06330350Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive CounsellingMaastricht University Medical Center